Point of Care Diagnostics Market Analysis and Forecast to 2031: By Product (Glucose Monitoring, Cardiometabolic Testing, Infectious Disease Testing, Blood Gas/Electrolytes Testing, Pregnancy & Fertility Testing, Tumor/Cancer Marker Testing), By Technology

Point of Care Diagnostics Market Analysis and Forecast to 2031: By Product (Glucose Monitoring, Cardiometabolic Testing, Infectious Disease Testing, Blood Gas/Electrolytes Testing, Pregnancy & Fertility Testing, Tumor/Cancer Marker Testing), By Technology (Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics, Immunoassays), By Application (Cardio Metabolic Testing, Infectious Disease Testing, Nephrology Testing, Drug-of-Abuse (DoA) Testing), By End-use (Hospitals, Diagnostic Centers, Research Laboratories, Home-Care Settings), and Region

The global point of care diagnostics market was valued at USD 32.2 billion in 2021 and it is anticipated to grow up to USD 76.4 billion by 2031, at a CAGR of 9.0% during the forecast period.


Point of care diagnostics allows medical staff and physicians to accurately achieve real-time lab-quality diagnostic results within minutes. Point of care testing devices utilize principles of lateral flow chromatography and immunoassays to analyze the whole blood. POCT includes blood glucose testing, blood gas and electrolytes analysis, rapid coagulation testing, rapid cardiac markers diagnostics, drugs of abuse screening, pregnancy testing and fecal occult blood analysis among others.

Market Trends and Drivers

POC tests can greatly improve the management of infectious diseases, especially in developing countries where access to timely medical care is a challenge and the healthcare infrastructure is antiquated and sparse. For instance, according to UNAIDS, around 20.6 million people were living with HIV in East and Southern Africa in 2018. Similarly, in 2019, 20,000 new HIV cases were registered in the Middle East and North Africa as per the UNAIDS Data 2020). In the Asia Pacific, an estimated 5.8 million people were suffering from HIV in 2019, led by India and China. According to UNAIDS, in 2019, approximately 2.1 million people in India were infected with HIV. The high prevalence of HIV is likely to boost the demand for point-of-care diagnostics, further accelerating the treatment of HIV infection. Hence, high prevalence of infectious diseases, coupled with the inadequate healthcare infrastructural facilities in developing countries, is expected to drive the adoption of POC testing.

Market Restraints and Challenges

The pricing pressure due to reimbursement cuts and lack of sufficient budgets affects the growth of the global POC diagnostics market. In 2013, the US government passed a healthcare reform bill, according to which manufacturers must pay a heavy 2.3% annual excise tax on medical devices. Similarly, France has focused on medical devices for cost containment to recover from the recession. The 2013 French budget included price cuts of a total of USD 157.6 million (EUR 115 million) in the medical sector, which comprises savings worth USD 102.8 million (EUR 75 million) from the ambulatory care sector and USD 54.8 million (EUR 40 million) from hospitals. In France, all the cost of patient care is rolled out into one prospective payment under the Diagnosis Related Group (DRG) system, making reimbursement a negligible factor. For instance, in the country, the reimbursement for diabetes technologies in outpatient settings is based on a tariff system. Reimbursable products and services, along with their respective tariffs, are added to the list of reimbursed products and services (LPPR). Blood glucose monitoring strips are reimbursed based on a single “generic” tariff, as French payers do not see the relevant difference in the various prices of BGM.

Global Point of Care Diagnostics Market Segmental Overview

The report analyses the global point of care diagnostics market based on product, technology, application, end use, and region.

Global Point of Care Diagnostics Market by Product

Based on product, it is segmented into glucose monitoring, cardiometabolic testing, blood gas/electrolytes testing, infectious disease testing, pregnancy and fertility testing, tumor/cancer marker testing and others. The Among these, glucose monitoring segment accounted for the largest share of the global Point of Care market, by product type, in 2021. Glucose monitoring products are used to continuously monitor and track glucose levels in the body, which also provides information regarding the amount of insulin being released. The use of such monitoring devices offers better glucose control and enables accurate treatment decisions. POC glucose monitoring kits make use of small amounts of blood (usually through a finger prick) for analyzing results, making them less invasive as compared to lab tests. These kits can also be easily used by elderly patients. Glucose monitoring kits also help patients with type I and type II diabetes to monitor their glucose levels and prevent complications. Moreover, growing prevalence of diabetes globally, ongoing technological advancements in blood glucose self-monitoring devices, and growing patient awareness about POC testing will propel the market growth.

Global Point of Care Diagnostics Market by Technology

Based on technology, it is segmented into lateral flow assays, dipsticks, microfluidics, molecular diagnostics, immunoassays and others. Among these, the Lateral flow assays segment, by platform type, accounted for the largest share of the global Point of Care market in 2021. Lateral flow assays (LFA) or lateral flow immunochromatographic assays are simple devices used to detect the presence or absence of target analytes in samples. These assays help in detecting and quantifying analytes in complex mixtures and provide results within 30 minutes after the sample is placed on the device. Lateral flow assay-based POC tests are increasingly being adopted as a replacement for lengthy, conventional laboratory procedures. POC diagnostic tests require less complex infrastructure and training, owing to which the cost of these tests is lower as compared to conventional laboratory diagnostic procedures. However, regulatory bodies often need the confirmation of results by using an independent method, which makes LFA tests suitable for only primary screening at the point of care. However, technological improvements may affect the apparatus cost and analysis duration of the test, which can hamper the adoption of this platform in the coming years.

Global Point of Care Diagnostics Market by Application

Based on application, it is segmented into cardio metabolic testing, infectious disease testing, nephrology testing, drug-of-abuse (DoA) testing and Others. Among them, the infectious disease segment segment accounted significant share in 2021 owing to the Rising demand for novel products regarding early and cost-effective detection of infectious diseases will influence the product demand. Rising laboratory capacity for the diagnosis of infectious diseases and early detection of emerging pandemic strains will spur the industry expansion. Growing prevalence of infectious disease in elderly people, new-born babies, and people with certain chronic illnesses coupled will impel the growth during analysis period. Additionally, increasing availability of rapid tests resulting in rising applications in faster disease diagnosis will impact the product demand in future. Flu segment will showcase robust growth during forecast period. As per WHO, the average worldwide burden of seasonal influenza is approximately 600 million cases, with 250,000-500,000 deaths and 3 million cases of severe sickness per year. According to CDC estimates, in the U.S. about 200,000 individuals are hospitalized and around 36,000 people die from flu and its complications every year. Thus, growing disease pervasiveness and innovation in diagnostic tools will drive the segment revenue.

Global Point of Care Diagnostics Market by End-use

Based on end-use, it is segmented into hospitals, clinics and others. The hospitals segment accounted for significant revenue size in 2021 owing to the Easy availability of the diagnostic products and presence of skilled workforce in hospitals. Moreover, sophisticated infrastructure, presence of skilled workforce and increasing number of hospital admissions will strengthen the segment growth. Furthermore, requirement of faster diagnostic kits in hospitals for better treatment option will further enhance the segment demand during the forecast period

Geographical Analysis of Global Point of Care Diagnostics Market

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America therapeutic respiratory devices market captured significant market share in 2021 and is expected to grow significantly during the forecast years. Rising prevalence of infectious diseases and growing application of POC tests for safe and early diagnosis will increase the demand for such rapid tests. Also, high research and development investment by governments and major market players for development of POC molecular diagnostic tests will foster the market revenue during the forecast timeline. Increasing cases of COVID-19 in the region will boost the usage of point of care molecular diagnostic kits to manage the disease efficiently. Moreover, surmounting use of PCR-based procedures for diagnosis and commercialization of real-time PCR products will further influence the regional demand

Major Players in the Global Point of Care Diagnostics Market COVID-19 Impact

The COVID-19 pandemic negatively affected the overall sales of most of the companies but had an positive impact on the point-of-care molecular diagnostics market because of the use of molecular diagnostic methods for COVID-19 testing. Lockdowns resulting from the COVID-19 pandemic caused people to delay undergoing health checkups, thus affecting the number of tests being performed and sales of reagents. However, a resurgence in testing numbers is seen as countries gradually ease restrictions on movement. With the COVID-19 pandemic, responding to infectious disease has become a pressing medical issue worldwide. In addition to the development of vaccines and therapeutic drugs, there is a growing call for the development of more precise and simple testing technologies and the expansion of testing structures. COVID-19 has also impacted the regulatory environment and practices, as governments and healthcare providers face unprecedented challenges. Regulatory authorities utilized methods to speed approval of diagnostic products. Companies have taken strategic developments to introduce COVID-19 rapid tests, sustain their revenues, and nullify the impact of COVID-19 on their operational capabilities.

Recent Developments

  • In January 2022, Roche launched its Cobas Pulse System in select countries accepting the CE Mark. This is Roche Diagnostics’ newest generation of connected point-of-care solutions for professional blood glucose management.
  • In October 2021, Thermo Fisher Scientific announced that it received Emergency Use Authorization (EUA) from the FDA to run COVID-19 tests from new saliva sample collection method with the Spectrum Solutions SpectrumDNA SDNA-1000 collection device, a high-throughput, automated COVID-19 testing system on the Amplitude Solution.
  • In June 2021, bioMérieux and Specific Diagnostics announced a co-exclusive distribution agreement for the SPECIFIC REVEAL Rapid AST system in Europe. The system is a perfect complement to bioMérieux’s BIOFIRE BCID2.
  • In October 2020, bioMérieux SA partnered with Africa Medical Supplies Platform (AMSP) to supply high-quality COVID-19 diagnostic solutions from the bioMérieux Pandemic Response Portfolio to African Union Member States.


Frequently Asked Questions

Q1. How big is the point of care diagnostics market?Ans. The global point of care diagnostics market size was USD 32.2 billion in 2021 and is anticipated to reach USD 76.4 billion in 2031, growing at a rate of 9.0% from 2022 to 2031.
Q2. What is the point of care diagnostics market growth rate?Ans. The growth rate of the point of care diagnostics market is 9.0%.
Q3. Which region holds a major market share for the sepsis diagnostics market?Ans. North America holds a major market share of the point of care diagnostics market in 2021.
Q4. Which segment accounted for the largest point of care diagnostics market share?Ans. By end user, the healthcare segment accounted for the largest point of care diagnostics market share.
Q5. Who are the key players in the sepsis diagnostics market?Ans. The global point of care diagnostics market report includes players such as are
Q6. What are the factors driving the point of care diagnostics market growth?Ans. The major factors driving the growth of the market are the rising incidence of HIV across the globe.
Q7. What are the key growth strategies of point of care diagnostics market players?Ans. The key growth strategies of point of care diagnostics market players are product launch and product approval.
Q8. Which region will provide more business opportunities for the point of care diagnostics market during the forecast period?Ans. The Asia-Pacific region will provide more business opportunities for the point of care diagnostics market during the forecast period.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.


Chapter 1. Market Introduction
1.1. Objectives of The Study
1.2. Market Definition And Research & Scope
1.3. Research Methodologies
1.4. Market Estimation Techniques
Chapter 2. Executive Summary
2.1. Summary
2.2. Key Highlights of The Market
Chapter 3. Protein A Resin Market Outlook
3.1. Protein A Resin Market Segmentation
3.2. Market Dynamics
3.2.1. Market Drivers
3.2.1.1. Driver 1
3.2.1.2. Driver 2
3.2.1.3. Driver 3
3.2.2. Market Restraints
3.2.2.1. Restraint 1
3.2.2.2. Restraint 2
3.2.3. Market Opportunities
3.2.3.1. Opportunity 1
3.2.3.2. Opportunity 2
3.3. Porter’s Five Forces Analysis
3.3.1. Threat of New Entrants
3.3.2. Threat of Substitutes
3.3.3. Bargaining Power of Buyers
3.3.4. Bargaining Power of Supplier
3.3.5. Competitive Rivalry
3.4. Pestle Analysis
3.5. Value Chain Analysis
3.5.1. Raw Material Suppliers
3.5.2. Manufacturers
3.5.3. Wholesalers and/or Retailers
3.6. Impact of The Russia And Ukraine War on The Sepsis Diagnostics Market
Chapter 4. The Economic Impact of COVID-19
4.1. Overall Impact of COVID-19
4.2. Impact of COVID-19 on The Sepsis Diagnostics Market
4.3. Economic Impact Analysis
Chapter 5. Protein A Resin Market by Product
5.1. Market Overview
5.2. Natural protein A
5.2.1. Market Size And Forecast, 2021-2031 ($Million)
5.2.2. Market Size And Forecast, by Region, 2021-2031 ($Million)
5.3. Recombinant protein A
5.3.1. Market Size And Forecast, 2021-2031 ($Million)
5.3.2. Market Size And Forecast, by Region, 2021-2031 ($Million)
Chapter 6. Protein A Resin Market by Application
6.1. Market Overview
6.2. Immunoprecipitation
6.2.1. Market Size And Forecast, 2021-2031 ($Million)
6.2.2. Market Size And Forecast, by Region, 2021-2031 ($Million)
6.3. Antibody Purification
6.3.1. Market Size And Forecast, 2021-2031 ($Million)
6.3.2. Market Size And Forecast, by Region, 2021-2031 ($Million)
Chapter 7. Protein A Resin Market by Matrix Type
7.1. Market Overview
7.2. Agarose-based Matrix
7.2.1. Market Size And Forecast, 2021-2031 ($Million)
7.2.2. Market Size And Forecast, by Region, 2021-2031 ($Million)
7.3. Glass Or Silica Gel-based Matrix
7.3.1. Market Size And Forecast, 2021-2031 ($Million)
7.3.2. Market Size And Forecast, by Region, 2021-2031 ($Million)
7.4. Organic Polymer-based Matrix
7.4.1. Market Size And Forecast, 2021-2031 ($Million)
7.4.2. Market Size And Forecast, by Region, 2021-2031 ($Million)
Chapter 8. Protein A Resin Market by End-use
8.1. Market Overview
8.2. Biopharmaceutical Companies
8.2.1. Market Size And Forecast, 2021-2031 ($Million)
8.2.2. Market Size And Forecast, by Region, 2021-2031 ($Million)
8.3. Clinical Research Laboratories
8.3.1. Market Size And Forecast, 2021-2031 ($Million)
8.3.2. Market Size And Forecast, by Region, 2021-2031 ($Million)
8.4. Academic Research Institutes
8.4.1. Market Size And Forecast, 2021-2031 ($Million)
8.4.2. Market Size And Forecast, by Region, 2021-2031 ($Million)
8.5. Contract Research Organizations
8.5.1. Market Size And Forecast, 2021-2031 ($Million)
8.5.2. Market Size And Forecast, by Region, 2021-2031 ($Million)
Chapter 9. Sepsis Diagnostics Market, by Region
9.1. Overview
9.2. North America
9.2.1. Key Market Trends And Opportunities
9.2.2. North America Protein A Resin Market Size And Forecast by Product, 2021-2031, ($Million)
9.2.3. North America Protein A Resin Market Size And Forecast by Application, 2021-2031, ($Million)
9.2.4. North America Protein A Resin Market Size And Forecast by Matrix Type, 2021-2031, ($Million)
9.2.5. North America Protein A Resin Market Size And Forecast by End-use, 2021-2031, ($Million)
9.2.6. North America Protein A Resin Market Size And Forecast by Country, 2021-2031, ($Million)
9.2.7. The U.S.
9.2.7.1. The U.S. Protein A Resin Market Size And Forecast by Product, 2021-2031, ($Million)
9.2.7.2. The U.S. Protein A Resin Market Size And Forecast by Application, 2021-2031, ($Million)
9.2.7.3. The U.S. Protein A Resin Market Size And Forecast by Matrix Type, 2021-2031, ($Million)
9.2.7.4. The U.S. Protein A Resin Market Size And Forecast by End-use, 2021-2031, ($Million)
9.2.8. Canada
9.2.8.1. Canada Protein A Resin Market Size And Forecast by Product, 2021-2031, ($Million)
9.2.8.2. Canada Protein A Resin Market Size And Forecast by Application, 2021-2031, ($Million)
9.2.8.3. Canada Protein A Resin Market Size And Forecast by Matrix Type, 2021-2031, ($Million)
9.2.8.4. Canada Protein A Resin Market Size And Forecast by End-use, 2021-2031, ($Million)
9.2.9. Mexico
9.2.9.1. Mexico Protein A Resin Market Size And Forecast by Product, 2021-2031, ($Million)
9.2.9.2. Mexico Protein A Resin Market Size And Forecast by Application, 2021-2031, ($Million)
9.2.9.3. Mexico Protein A Resin Market Size And Forecast by Matrix Type, 2021-2031, ($Million)
9.2.9.4. Mexico Protein A Resin Market Size And Forecast by End-use, 2021-2031, ($Million)
9.3. Europe
9.3.1. Key Market Trends And Opportunities
9.3.2. Europe Protein A Resin Market Size And Forecast by Product, 2021-2031, ($Million)
9.3.3. Europe Protein A Resin Market Size And Forecast by Application, 2021-2031, ($Million)
9.3.4. Europe Protein A Resin Market Size And Forecast by Matrix Type, 2021-2031, ($Million)
9.3.5. Europe Protein A Resin Market Size And Forecast by End-use, 2021-2031, ($Million)
9.3.6. Europe Protein A Resin Market Size And Forecast by Country, 2021-2031, ($Million)
9.3.7. Germany
9.3.7.1. Germany Protein A Resin Market Size And Forecast by Product, 2021-2031, ($Million)
9.3.7.2. Germany Protein A Resin Market Size And Forecast by Application, 2021-2031, ($Million)
9.3.7.3. Germany Protein A Resin Market Size And Forecast by Matrix Type, 2021-2031, ($Million)
9.3.7.4. Germany Protein A Resin Market Size And Forecast by End-use, 2021-2031, ($Million)
9.3.8. France
9.3.8.1. France Protein A Resin Market Size And Forecast by Product, 2021-2031, ($Million)
9.3.8.2. France Protein A Resin Market Size And Forecast by Application, 2021-2031, ($Million)
9.3.8.3. France Protein A Resin Market Size And Forecast by Matrix Type, 2021-2031, ($Million)
9.3.8.4. France Protein A Resin Market Size And Forecast by End-use, 2021-2031, ($Million)
9.3.9. U.K
9.3.9.1. U.K. Protein A Resin Market Size And Forecast by Product, 2021-2031, ($Million)
9.3.9.2. U.K. Protein A Resin Market Size And Forecast by Application, 2021-2031, ($Million)
9.3.9.3. U.K. Protein A Resin Market Size And Forecast by Matrix Type, 2021-2031, ($Million)
9.3.9.4. U.K. Protein A Resin Market Size And Forecast by End-use, 2021-2031, ($Million)
9.3.10. Spain
9.3.10.1. Spain Protein A Resin Market Size And Forecast by Product, 2021-2031, ($Million)
9.3.10.2. Spain Protein A Resin Market Size And Forecast by Application, 2021-2031, ($Million)
9.3.10.3. Spain Protein A Resin Market Size And Forecast by Matrix Type, 2021-2031, ($Million)
9.3.10.4. Spain Protein A Resin Market Size And Forecast by End-use, 2021-2031, ($Million)
9.3.11. Italy
9.3.11.1. Italy Protein A Resin Market Size And Forecast by Product, 2021-2031, ($Million)
9.3.11.2. Italy Protein A Resin Market Size And Forecast by Application, 2021-2031, ($Million)
9.3.11.3. Italy Protein A Resin Market Size And Forecast by Matrix Type, 2021-2031, ($Million)
9.3.11.4. Italy Protein A Resin Market Size And Forecast by End-use, 2021-2031, ($Million)
9.3.12. Russia
9.3.12.1. Russia Protein A Resin Market Size And Forecast by Product, 2021-2031, ($Million)
9.3.12.2. Russia Protein A Resin Market Size And Forecast by Application, 2021-2031, ($Million)
9.3.12.3. Russia Protein A Resin Market Size And Forecast by Matrix Type, 2021-2031, ($Million)
9.3.12.4. Russia Protein A Resin Market Size And Forecast by End-use, 2021-2031, ($Million)
9.3.13. Rest of Europe
9.3.13.1. Rest of Europe Protein A Resin Market Size And Forecast by Product, 2021-2031, ($Million)
9.3.13.2. Rest of Europe Protein A Resin Market Size And Forecast by Application, 2021-2031, ($Million)
9.3.13.3. Rest of Europe Protein A Resin Market Size And Forecast by Matrix Type, 2021-2031, ($Million)
9.3.13.4. Rest of Europe Protein A Resin Market Size And Forecast by End-use, 2021-2031, ($Million)
9.4. Asia-Pacific
9.4.1. Key Market Trends And Opportunities
9.4.2. Asia-Pacific Protein A Resin Market Size And Forecast by Country, 2021-2031, ($Million)
9.4.3. Asia-Pacific Protein A Resin Market Size And Forecast by Product, 2021-2031, ($Million)
9.4.4. Asia-Pacific Protein A Resin Market Size And Forecast by Application, 2021-2031, ($Million)
9.4.5. Asia-Pacific Protein A Resin Market Size And Forecast by Matrix Type, 2021-2031, ($Million)
9.4.6. Asia-Pacific Protein A Resin Market Size And Forecast by End-use, 2021-2031, ($Million)
9.4.7. China
9.4.7.1. China Protein A Resin Market Size And Forecast by Product, 2021-2031, ($Million)
9.4.7.2. China Protein A Resin Market Size And Forecast by Application, 2021-2031, ($Million)
9.4.7.3. China Protein A Resin Market Size And Forecast by Matrix Type, 2021-2031, ($Million)
9.4.7.4. China Protein A Resin Market Size And Forecast by End-use, 2021-2031, ($Million)
9.4.8. India
9.4.8.1. India Protein A Resin Market Size And Forecast by Product, 2021-2031, ($Million)
9.4.8.2. India Protein A Resin Market Size And Forecast by Application, 2021-2031, ($Million)
9.4.8.3. India Protein A Resin Market Size And Forecast by Matrix Type, 2021-2031, ($Million)
9.4.8.4. India Protein A Resin Market Size And Forecast by End-use, 2021-2031, ($Million)
9.4.9. Japan
9.4.9.1. Japan Protein A Resin Market Size And Forecast by Product, 2021-2031, ($Million)
9.4.9.2. Japan Protein A Resin Market Size And Forecast by Application, 2021-2031, ($Million)
9.4.9.3. Japan Protein A Resin Market Size And Forecast by Matrix Type, 2021-2031, ($Million)
9.4.9.4. Japan Protein A Resin Market Size And Forecast by End-use, 2021-2031, ($Million)
9.4.10. South Korea
9.4.10.1. South Korea Protein A Resin Market Size And Forecast by Product, 2021-2031, ($Million)
9.4.10.2. South Korea Protein A Resin Market Size And Forecast by Application, 2021-2031, ($Million) South Korea Protein A Resin Market Size And Forecast by Matrix Type, 2021-2031, ($Million)
9.4.10.3. South Korea Protein A Resin Market Size And Forecast by End-use, 2021-2031, ($Million)
9.4.11. Rest of APAC
9.4.11.1. Rest of APAC Protein A Resin Market Size And Forecast by Product, 2021-2031, ($Million)
9.4.11.2. Rest of APAC Protein A Resin Market Size And Forecast by Application, 2021-2031, ($Million)
9.4.11.3. Rest of APAC Protein A Resin Market Size And Forecast by Matrix Type, 2021-2031, ($Million)
9.4.11.4. Rest of APAC Protein A Resin Market Size And Forecast by End-use, 2021-2031, ($Million)
9.5. Rest of The World
9.5.1. Key Market Trends And Opportunities
9.5.2. Rest of The World Protein A Resin Market Size And Forecast by Product, 2021-2031, ($Million)
9.5.3. Rest of The World Protein A Resin Market Size And Forecast by Application, 2021-2031, ($Million)
9.5.4. Rest of The World Protein A Resin Market Size And Forecast by Matrix Type, 2021-2031, ($Million)
9.5.5. Rest of The World Protein A Resin Market Size And Forecast by End-use, 2021-2031, ($Million)
9.5.6. Rest of The World Protein A Resin Market Size And Forecast by Country, 2021-2031, ($Million)
9.5.7. Latin America
9.5.7.1. Latin America Protein A Resin Market Size And Forecast by Product, 2021-2031, ($Million)
9.5.7.2. Latin America Protein A Resin Market Size And Forecast by Application, 2021-2031, ($Million)
9.5.7.3. Latin America Protein A Resin Market Size And Forecast by Matrix Type, 2021-2031, ($Million)
9.5.7.4. Latin America Protein A Resin Market Size And Forecast by End-use, 2021-2031, ($Million)
9.5.8. Middle East
9.5.8.1. Middle East Protein A Resin Market Size And Forecast by Product, 2021-2031, ($Million)
9.5.8.2. Middle East Protein A Resin Market Size And Forecast by Application, 2021-2031, ($Million)
9.5.8.3. Middle East Protein A Resin Market Size And Forecast by Matrix Type, 2021-2031, ($Million)
9.5.8.4. Middle East Protein A Resin Market Size And Forecast by End-use, 2021-2031, ($Million)
9.5.9. Africa
9.5.9.1. Africa Protein A Resin Market Size And Forecast by Product, 2021-2031, ($Million)
9.5.9.2. Africa Protein A Resin Market Size And Forecast by Application, 2021-2031, ($Million) Africa Protein A Resin Market Size And Forecast by Matrix Type, 2021-2031, ($Million)
9.5.9.3. Africa Protein A Resin Market Size And Forecast by End-use, 2021-2031, ($Million)
Chapter 10. Competitive Landscape
10.1. Market Overview
10.2. Market Share Analysis/Key Player Positioning
10.3. Developmental Strategy Benchmarking
10.3.1. New Testing Type Development
10.3.2. Chemical-based Launches
10.3.3. Business Expansions
10.3.4. Partnerships, Joint Ventures, And Collaborations
10.3.5. Mergers And Acquisitions
Chapter 11. Company Profiles
11.1. GE Healthcare (US)
11.1.1. Company Snapshot
11.1.2. Financial Performance
11.1.3. Chemical-based offerings
11.1.4. Key Strategic Initiatives
11.1.5. SWOT Analysis
11.2. Merck Millipore (Germany)
11.2.1. Company Snapshot
11.2.2. Financial Performance
11.2.3. Chemical-based offerings
11.2.4. Key Strategic Initiatives
11.2.5. SWOT Analysis
11.3. Repligen Corporation (US)
Company Snapshot
11.3.1. Financial Performance
11.3.2. Chemical-based offerings
11.3.3. Key Strategic Initiatives
11.3.4. SWOT Analysis
11.4. T2 Thermo Fisher Scientific (US)
11.4.1. Company Snapshot
11.4.2. Financial Performance
11.4.3. Chemical-based offerings
11.4.4. Key Strategic Initiatives
11.4.5. SWOT Analysis
11.5. Tosoh Bioscience (Japan)
11.5.1. Company Snapshot
11.5.2. Financial Performance
11.5.3. Chemical-based offerings
11.5.4. Key Strategic Initiatives
11.5.5. SWOT Analysis
11.6. Purolite Corporation (US)
11.6.1. Company Snapshot
11.6.2. Financial Performance
11.6.3. Chemical-based offerings
11.6.4. Key Strategic Initiatives
11.6.5. SWOT Analysis
11.7. Novasep Holding SAS (France)
11.7.1. Company Snapshot
11.7.2. Financial Performance
11.7.3. Chemical-based offerings
11.7.4. Key Strategic Initiatives
11.7.5. SWOT Analysis
11.8. Agilent Technologies (US)
11.8.1. Company Snapshot
11.8.2. Financial Performance
11.8.3. Chemical-based offerings
11.8.4. Key Strategic Initiatives
11.8.5. SWOT Analysis
11.9. GenScript Biotech Corporation (China)
11.9.1. Company Snapshot
11.9.2. Financial Performance
11.9.3. Chemical-based offerings
11.9.4. Key Strategic Initiatives
11.9.5. SWOT Analysis
11.10. PerkinElmer (US)
11.10.1. Company Snapshot
11.10.2. Financial Performance
11.10.3. Chemical-based offerings
11.10.4. Key Strategic Initiatives
11.10.5. SWOT Analysis
*The List of Company Is Subject To Change During The Final Compilation of The Report

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings